Spondyloarthropathies: an independent cardiovascular risk factor?

Joint Bone Spine. 2010 Dec;77(6):542-5. doi: 10.1016/j.jbspin.2010.05.001. Epub 2010 Jun 19.

Abstract

An increase in cardiovascular mortality and morbidity has been convincingly documented in rheumatoid arthritis. Data on spondyloarthropathies are more limited. Here, we discuss published studies indicating that patients with spondyloarthropathies are at increased risk for cardiovascular disease. The excess risk is probably multifactorial, being related both to chronic systemic inflammation and to high prevalences of conventional cardiovascular risk factors. Cardiovascular risk management in patients with spondyloarthropathies requires optimal control of disease activity combined with interventions targeting conventional cardiovascular risk factors.

Publication types

  • Review

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Antirheumatic Agents / adverse effects
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / epidemiology
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / prevention & control
  • Comorbidity
  • Cyclooxygenase 2 Inhibitors / adverse effects
  • Female
  • Humans
  • Life Style
  • Male
  • Middle Aged
  • Risk Factors
  • Spondylarthropathies / drug therapy
  • Spondylarthropathies / epidemiology*
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / epidemiology
  • Survival Rate

Substances

  • Anticholesteremic Agents
  • Antirheumatic Agents
  • Cyclooxygenase 2 Inhibitors